Asset Details
Do you wish to reserve the book?
Investigation of a simple suspension method for orexin receptor antagonist tablets
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Investigation of a simple suspension method for orexin receptor antagonist tablets
Do you wish to request the book?
Investigation of a simple suspension method for orexin receptor antagonist tablets
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Investigation of a simple suspension method for orexin receptor antagonist tablets
2026
Overview
Background
A simple suspension method is used in medical practice to administer several orexin receptor antagonists for patients with dysphagia; however, detailed suspension and passage through catheter evaluations have not been performed. Therefore, to safely administer orexin receptor antagonists using the simple suspension method in patients with dysphagia, this study evaluated the disintegration, suspension, passage through the catheter, and drug recovery after passage of Belsomra
®
20 mg (suvorexant), Dayvigo
®
10 mg (lemborexant), and Quviviq
®
50 mg (daridorexant) tablets through a catheter.
Methods
Disintegration and suspension of Belsomra
®
20 mg, Dayvigo
®
10 mg, and Quviviq
®
50 mg tablets, and passage through the catheter were visually confirmed. Drug recovery after passage through the catheter was quantified using liquid chromatography-mass spectrometry.
Results
In this study, there was no disintegration and suspension of Belsomra
®
20 mg tablets. However, Dayvigo
®
10 mg and Quviviq
®
50 mg tablets demonstrated disintegration and suspension, including passage through the catheter after rapid and complete disintegration. Drug recovery after catheter passage was >80% for Dayvigo
®
10 mg without flushing and for Quviviq
®
50 mg after two flushes.
Conclusion
As the disintegration and suspension properties of Belsomra
®
20 mg tablet could not be confirmed, the conventional simple suspension method is not suitable for this product. However, Dayvigo
®
10 mg and Quviviq
®
50 mg tablets showed potential suitability for the simple suspension method.
